Exenatide regulates pancreatic islet integrity and insulin sensitivity in baboons by T.V. Fiorentino et al.
Exenatide regulates pancreatic islet integrity
and insulin sensitivity in the nonhuman primate
baboon Papio hamadryas
Teresa Vanessa Fiorentino, … , Ralph A. DeFronzo, Franco
Folli
JCI Insight. 2019;4(20):e93091. https://doi.org/10.1172/jci.insight.93091.
 
The glucagon-like peptide-1 receptor agonist exenatide improves glycemic control by
several and not completely understood mechanisms. Herein, we examined the effects of
chronic intravenous exenatide infusion on insulin sensitivity, b cell and a cell function and
relative volumes, and islet cell apoptosis and replication in nondiabetic nonhuman primates
(baboons). At baseline, baboons received a 2-step hyperglycemic clamp followed by an l-
arginine bolus (HC/A). After HC/A, baboons underwent a partial pancreatectomy (tail
removal) and received a continuous exenatide (n = 12) or saline (n = 12) infusion for 13
weeks. At the end of treatment, HC/A was repeated, and the remnant pancreas (head-body)
was harvested. Insulin sensitivity increased dramatically after exenatide treatment and was
accompanied by a decrease in insulin and C-peptide secretion, while the insulin
secretion/insulin resistance (disposition) index increased by about 2-fold. b, a, and d cell
relative volumes in exenatide-treated baboons were significantly increased compared with
saline-treated controls, primarily as the result of increased islet cell replication. Features of
cellular stress and secretory dysfunction were present in islets of saline-treated baboons
and absent in islets of exenatide-treated baboons. In conclusion, chronic administration of
exenatide exerts proliferative and cytoprotective effects on b, a, and d cells and produces a
robust increase in insulin sensitivity in nonhuman primates.
Research Article Endocrinology
Find the latest version:
https://jci.me/93091/pdf
1insight.jci.org   https://doi.org/10.1172/jci.insight.93091
R E S E A R C H  A R T I C L E
Authorship note: TVF, FC, and AMD 
are co–first authors.
Conflict of interest: The authors have 
declared that no conflict of interest 
exists.
Copyright: © 2019, American Society 
for Clinical Investigation.
Submitted: January 29, 2019 
Accepted: September 5, 2019 
Published: September 19, 2019.
Reference information: JCI Insight. 
2019;4(20):e93091. 
https://doi.org/10.1172/jci.
insight.93091.
Exenatide regulates pancreatic islet 
integrity and insulin sensitivity  
in the nonhuman primate baboon  
Papio hamadryas
Teresa Vanessa Fiorentino,1,2 Francesca Casiraghi,2,3 Alberto M. Davalli,2,4 Giovanna Finzi,5  
Stefano La Rosa,6 Paul B. Higgins,7 Gregory A. Abrahamian,8 Alessandro Marando,5  
Fausto Sessa,5 Carla Perego,9 Rodolfo Guardado-Mendoza,2 Subhash Kamath,2 Andrea Ricotti,2 
Paolo Fiorina,10 Giuseppe Daniele,2 Ana M. Paez,2 Francesco Andreozzi,1,2 Raul A. Bastarrachea,7 
Anthony G. Comuzzie,7 Amalia Gastaldelli,2,11 Alberto O. Chavez,2 Eliana S. Di Cairano,9  
Patrice Frost,7 Livio Luzi,3,12 Edward J. Dick,7 Glenn A. Halff,8 Ralph A. DeFronzo,2  
and Franco Folli2,7,13
1Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy. 2Division of 
Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. 
3Department of Biomedical Sciences for Health, University of Milan, Milan, Italy. 4Department of Medicine, Endocrinology 
Unit, Ospedale San Raffaele, Milan, Italy. 5Unit of Pathology, Ospedale di Circolo and Department of Medicine and Surgery, 
University of Insubria, Varese, Italy. 6Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital and 
University of Lausanne, Lausanne, Switzerland. 7Southwest National Primate Research Center, Texas Biomedical Research 
Institute, San Antonio, Texas, USA. 8Department of Surgery, Transplant Center, University of Texas Health Science Center 
at San Antonio, San Antonio, Texas, USA. 9Department of Pharmacology and Biomolecular Science, University of Milan, 
Milan, Italy. 10Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, Division of Health Science, 
Harvard University, Boston, Massachusetts, USA. 11Institute of Clinical Physiology, National Research Council, Pisa, Italy. 
12Metabolism Research Centre, IRCCS Policlinico San Donato, Milan, Italy. 13Department of Health Science, University of 
Milan, Milan, Italy.
Introduction
Type 1 and type 2 diabetes (T1D, T2D) are characterized by progressive β cell dysfunction coupled with 
declining β cell mass (1, 2). At the time of  T2D diagnosis, β cell function is reduced by about 80% (3) and β 
cell mass is reduced to 30%–50% (4, 5), while in T1D the β cell deficit is severer and averages 70%–100% (6). 
The glucagon-like peptide-1 receptor agonist exenatide improves glycemic control by several and 
not completely understood mechanisms. Herein, we examined the effects of chronic intravenous 
exenatide infusion on insulin sensitivity, β cell and α cell function and relative volumes, and islet 
cell apoptosis and replication in nondiabetic nonhuman primates (baboons). At baseline, baboons 
received a 2-step hyperglycemic clamp followed by an l-arginine bolus (HC/A). After HC/A, baboons 
underwent a partial pancreatectomy (tail removal) and received a continuous exenatide (n = 12) or 
saline (n = 12) infusion for 13 weeks. At the end of treatment, HC/A was repeated, and the remnant 
pancreas (head-body) was harvested. Insulin sensitivity increased dramatically after exenatide 
treatment and was accompanied by a decrease in insulin and C-peptide secretion, while the insulin 
secretion/insulin resistance (disposition) index increased by about 2-fold. β, α, and δ cell relative 
volumes in exenatide-treated baboons were significantly increased compared with saline-treated 
controls, primarily as the result of increased islet cell replication. Features of cellular stress and 
secretory dysfunction were present in islets of saline-treated baboons and absent in islets of 
exenatide-treated baboons. In conclusion, chronic administration of exenatide exerts proliferative 
and cytoprotective effects on β, α, and δ cells and produces a robust increase in insulin sensitivity in 
nonhuman primates.
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A dimorphic histology of  long-duration T1D has been reported, with 70% of subjects showing only insu-
lin-deficient islets and the remaining 30% showing numerous insulin-positive cells (7, 8). Importantly, residual 
β cell function has been demonstrated 30–40 years after the onset of  T1D with ultrasensitive C-peptide assays 
(9). Nevertheless, the loss of  β cells remains fundamental to the etiology of  both forms of  diabetes.
Preventing the loss and enhancing proliferation of  β cells is essential for maintaining long-term meta-
bolic control in T1D and T2D. However, the 2 most commonly prescribed antidiabetic drugs (metformin 
and sulfonylureas) are not effective in this regard (10–14), and sulfonylureas may even promote β cell 
loss (15). Synthetic long-acting glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) exhibit 
glucoregulatory activities similar to native GLP-1, including glucose-dependent enhancement of  insulin 
secretion and inhibition of  glucagon release, delayed gastric emptying, and reduced food intake (16–19). 
Importantly, GLP-1 RAs also show proliferative effects, including enhanced β cell replication and reduced 
apoptosis (20). Nevertheless, these in vivo cellular findings have been described only in rodents, although in 
vitro evidence for these effects has been reported in human tissues (21–26). It is unknown whether GLP-1 
RAs can stimulate β cell growth in vivo in humans, and the tissue sampling required to directly test these 
effects in a controlled setting is excessively invasive.
The baboon is recognized as an important preclinical model of  human obesity, insulin resistance, and 
T2D that provides high translational value (27–31). Compared with other species, the relative volume, 
distribution, and responses of  islet cells are more consistent between human and nonhuman primates (32). 
In the present study, we generated a partially pancreatectomized model of  diminished β cell mass and islet 
cellular stress in baboons and tested the in vivo effects of  chronic administration of  the GLP-1 RA exen-
atide on: (a) islet cell replication, apoptosis, transdifferentiation (neogenesis), and ultrastructural integrity; 
(b) α and β cell secretory function; and (c) insulin sensitivity. Our results provide the first direct in vivo evi-
dence, we believe, for enhanced β cell replication, decreased apoptosis, and reduced cellular stress following 
chronic GLP-1 RA administration in a nonhuman primate.
Results
Body composition and plasma chemistries. The study population comprised 28 female nondiabetic baboons (Papio 
hamadryas sp.). Twenty-four animals underwent abdominal surgery with resection of  the pancreatic tail (par-
tial pancreatectomy [PPx]) and then were randomized to receive a chronic (13-week) intravenous infusion of  
saline (n = 12) or exenatide (n = 12). Four animals underwent sham abdominal surgery without PPx followed 
by a chronic saline intravenous infusion (sham-operated, saline-treated [SHAM]) for 13 weeks.
At the end of  the study, serum exenatide levels were higher (758 ± 162 pg/mL) in the exenatide group 
compared with the saline group (0.0 pg/mL). Body weight was significantly lower in the saline-treated 
group (16.7 ± 0.7 kg vs. 18.5 ± 0.7 kg, P = 0.01) at study end, whereas it did not change significantly in the 
exenatide group (17.2 ± 0.6 kg vs. 18.2 ± 0.8 kg, P = 0.08) (Supplemental Figure 1A; supplemental material 
available online with this article; https://doi.org/10.1172/jci.insight.93091DS1). Body composition analy-
sis showed that lean mass was maintained in the exenatide group (15.2 ± 0.5 kg vs. 15.6 ± 0.4 kg, P = 0.24) 
but decreased in the saline-treated control baboons (16.1 ± 0.5 kg vs. 15.0 ± 0.6 kg, P = 0.03, Supplemental 
Figure 1B). A significant decrease in fat mass was observed after treatment with exenatide (1.54 ± 0.45 vs. 
0.93 ± 0.20 kg, P ≤ 0.05) and saline (1.27 ± 0.24 vs. 0.86 ± 0.21 kg, P ≤ 0.05, Supplemental Figure 1C). The 
SHAM group did not undergo any significant changes in body composition or body weight over the study 
period. Food consumption was similar in the 3 groups, indicating that exenatide did not decrease energy 
intake (Supplemental Figure 1D). No anorexia, vomiting, diarrhea, or behavior changes were observed in 
animals treated with exenatide or saline. Clinical chemistries assessed before and after treatments did not 
show any significant change in the 3 study groups (Table 1). Specifically, there was no increase in plasma 
amylase after exenatide treatment. A decrease in Hb was observed in both saline- and exenatide-treated 
groups with no significant difference in Hb changes between the 2 study arms, suggesting that surgery and 
long-term catheterization may have contributed to the decrease in Hb.
Exenatide improved β cell function and insulin sensitivity and induced β cell rest. Plasma insulin and C-peptide con-
centrations during the 2-step hyperglycemic clamp are shown in Figure 1, A–F. The insulin secretory rate (ISR) 
(150–180 minutes) decreased significantly after exenatide treatment (149 ± 17 pmol/kg/min vs. 111 ± 16 pmol/
kg/min, P < 0.01) and did not change in the saline-treated (116 ± 11 pmol/kg/min vs. 104 ± 10 pmol/kg/min, 
P = 0.20) and SHAM (165 ± 9 pmol/kg/min vs. 184 ± 27 pmol/kg/min, P = 0.47) control groups. Plasma 
insulin and C-peptide concentrations were significantly lower (P < 0.05) after exenatide treatment at multiple 
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time points during the hyperglycemic clamp (Figure 1, A and B), including during the arginine stimulation test 
(180–210 minutes). There were no significant changes in either the plasma insulin or C-peptide responses in the 
saline-treated (Figure 1, C and D) or SHAM (Figure 1, E and F) groups. Similar results were obtained whether 
one used the periods of 90–180, 0–90, or 60–90 minutes. No significant differences in the plasma glucose levels 
during the hyperglycemic clamp were observed between the 3 study groups (Supplemental Figure 2A). Plasma 
glucagon concentrations were not changed after treatment in any of the groups (Supplemental Figure 2B). The 
AUC for plasma insulin and C-peptide concentrations (0–210 minutes) was significantly reduced by exenatide 
treatment while no significant changes were observed in saline-treated and SHAM groups (Figure 2, A and B).
Exenatide treatment resulted in a marked improvement in whole-body insulin sensitivity as demonstrated 
by the insulin-stimulated glucose disposal (M) and the increased ratio of M value and insulin concentrations 
during the clamp procedure (M/I; refs. 3, 27, 29) after treatment compared with baseline (Figure 2C and Supple-
mental Figure 3A); this could not be explained by changes in body weight or body composition. After exenatide 
treatment β cell function, estimated by the insulin secretion/insulin resistance (disposition) index (calculated by 
multiplying the ISR by insulin sensitivity) increased almost 2-fold (Figure 2D). No differences in insulin sensitiv-
ity or insulin secretion were found after treatment in the saline-treated and SHAM control groups (Figure 2, C 
and D). The relationship between insulin sensitivity and insulin secretion at baseline and after treatment for the 
3 study groups is shown in Supplemental Figure 3B. No significant differences in hepatic insulin clearance were 
found between baseline and study end in each study group (Supplemental Figure 3C).
Western blot analysis revealed that in skeletal muscle the only significant change in insulin signaling 
proteins was an increase in Akt Ser473 phosphorylation in exenatide-treated animals (P = 0.03) (Supple-
mental Figure 4). Expression and phosphorylation of  the other key proteins involved in insulin signal-
ing, including insulin receptor–β (IR-β), insulin receptor substrate-1 (IRS-1), extracellular signal–regulated 
kinase (ERK), Jun N-terminal kinase (JNK), phosphatase and tensin homolog (PTEN), and PH domain 
and leucine-rich repeat-containing protein phosphatase 1 (PHLPP1) did not differ between exenatide- and 
saline-treated groups. In livers of  exenatide-treated animals, the only significant change was a decrease in 
ERK phosphorylation (P = 0.03) (Supplemental Figure 5).
Table 1. Effects of treatments with exenatide, saline, and SHAM normal–glucose tolerant baboons on several metabolic and clinical 
chemistry parameters
EXENATIDE SALINE SHAM
BASAL EOS BASAL EOS BASAL EOS
Biochemical variables Mean ± SD Mean ± SD P Mean ± SD Mean ± SD P Mean ± SD Mean ± SD P
Total Hb (g/dL) 12.9 ± 2.0 10.6 ± 2.5 0.03 13.3 ± 1.2 12.1 ± 2.5 NS 11.8 ± 1.1 12.4 ± 1.8 NS
HbA1c (%) 4.1 ± 0.3 4.6 ± 0.8 NS 4.1 ± 0.3 4. ± 0.7 NS 4.3 ± 0.4 4.5 ± 0.5 NS
TPROT (g/dL) 7.6 ± 1.4 7.8 ± 1.1 NS 7.1 ± 0.9 8.48 ± 1.6 NS 5.3 ± 0.3 7.8 ± 1.4 NS
ALB (g/dL) 4.1 ± 0.8 3.6 ± 0.8 NS 3.9 ± 0.4 3.83 ± 0.4 NS 2.8 ± 0.3 4.1 ± 0.6 NS
TRIG (mg/dL) 62 ± 29 69 ± 28 NS 58 ± 18 89.9 ± 61 NS 53 ± 18 64 ± 21 NS
CHOL (mg/dL) 111 ± 22 122 ± 24 NS 106 ± 16 118 ± 17 NS 73 ± 20 91 ± 14 NS
LDL (mg/dL) 52 ± 12 57 ± 14 NS 51 ± 11 54.8 ± 11 NS 35 ± 9 42 ± 11 NS
HDL (mg/dL) 47 ± 12 51 ± 18 NS 43 ± 7 45.2 ± 12 NS 27 ± 10 37 ± 7 NS
LDH (U/L) 137 ± 26 156 ± 69 NS 169 ± 69 135 ± 38 NS 119 ± 14 162 ± 85 NS
ALT (U/L) 29 ± 6 26 ± 13 NS 40 ± 23 58.6 ± 51 NS 21 ± 5 25 ± 4 NS
TBILI (mg/dL) 0.2 ± 0.05 0.2 ± 0.05 NS 0.3 ± 0.09 0.24 ± 0.05 NS 0.2 ± 0.05 0.4 ± 0.03 NS
DBILI (mg/dL) 0.1 ± 0.04 0.1 ± 0.05 NS 0.2 ± 0.1 0.16 ± 0.05 NS 0.1 ± 0.01 0.3 ± 0.03 NS
Amylase (U/L) 156 ± 82 163 ± 91 NS 198 ± 183 165 ± 46 NS 144 ± 39 176 ± 31 NS
BUN (mg/dL) 11 ± 3 11 ± 3 NS 10 ± 3 12.6 ± 4 NS 9 ± 3 11 ± 5 NS
CREAT (mg/dL) 1.0 ± 0.2 1.0 ± 0.2 NS 1.0 ± 0.08 0.97 ± 0.2 NS 0.8 ± 0.1 1.0 ± 0.1 NS
Ca (mg/dL) 1.0 ± 0.3 1.2 ± 0.3 NS 1.2 ± 0.4 1.38 ± 0.4 NS 0.7 ± 0.2 1.1 ± 0.3 NS
Cl (mEq/L) 110 ± 12 107 ± 4 NS 108 ± 7 108 ± 3 NS 106 ± 13 107 ± 3 NS
Na (mEq/L) 143 ± 15 138 ± 5 NS 141 ± 9 139 ± 4 NS 135 ± 13 136 ± 1 NS
PHOS (mg/dL) 4.3 ± 0.7 4.6 ± 1.4 NS 4.0 ± 0.9 4.3 ± 1.0 NS 3.6 ± 0.5 5.2 ± 1.9 NS
n = 28 baboons. EOS, end of the study; Hb, hemoglobin; HbA1c, glycated hemoglobin; TPROT, total proteins; ALB, albumin; TRIG, triglycerides; CHOL, total 
cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LDH, lactate dehydrogenase; ALT, alanine aminotransferases; TBILI, total bilirubin; 
DBILI, direct bilirubin; BUN, blood urea nitrogen; CREAT, creatinine; Ca, calcium; Cl, chloride; Na, sodium; PHOS, phosphorus.
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Exenatide promoted islet cell replication and differentiation and reduced apoptosis. Of  particular note, 
in baboons that served as anatomic controls, islet β cell and α cell volumes in the head-body were 
significantly reduced (by 25%–33%), compared with the tail, while δ cell volumes were not different 
between regions (Figure 3A). In baboons that received saline for 13 weeks, at study end islet volume 
in the head-body region was significantly reduced compared with the tail region (Figure 3B). In exen-
atide-treated baboons, at study end islet volume in the head-body region was unchanged compared 
with the tail region (Figure 3B), and, importantly, it was higher than that in the head-body region of  
saline-treated animals (P = 0.02, Figure 3B). Notably, because islet volume in anatomic controls and 
saline-treated baboons is normally lower in the head-body versus tail, an “unchanged” islet volume in 
Figure 1. Effect of exenatide on insulin and C-peptide secretion. Dynamics of insulin (A, C, E) and C-peptide (B, D, F) secretion during the 2-step hypergly-
cemic clamps performed before (●) and after (□) treatments with exenatide (left), saline (middle), and saline in SHAM-operated (right) baboons. Number 
of baboons: 12 in exenatide group, 12 in saline group, and 4 in SHAM group. Comparisons between baseline and after-treatment data were performed by 
Wilcoxon’s test. *P < 0.05.
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the exenatide group indicates a growth-promoting effect of  exenatide on islet volume. In saline-treated 
baboons, at study end β cell volume in the head-body region also was significantly reduced compared 
with the tail region (3.1 ± 0.8% vs. 5.5 ± 1.6%, P = 0.003, Figure 3C). In marked contrast, at study 
end β cell volume in the head-body of  pancreata from exenatide-treated animals was not significantly 
different from that in the tail before treatment (5.6 ± 2.6% vs. 4.7 ± 1.6%, Figure 3C), and it was sig-
nificantly increased compared with the β cell volume in the head-body region of  the anatomic control 
group (4.7 ± 1.6% vs. 3.2 ± 1.2%, P = 0.01) and of  saline-treated baboons (4.7 ± 1.6% vs. 3.1 ± 0.8, P 
= 0.01), indicating a positive effect of  exenatide on β cell proliferation. Similar changes were observed 
for α cell volumes (saline group: 2.6 ± 1.7 vs. 0.7 ± 0.6%, P = 0.003; and exenatide group: 2.1 ± 1.4% 
vs. 1.6 ± 0.9%, P = NS; P = 0.02 for exenatide vs. saline at the study end, Figure 3D) and for δ cell 
volumes (saline group: 0.7 ± 0.4% vs. 0.3 ± 0.3%, P = 0.002; and exenatide group: 0.7 ± 0.6% vs. 
0.8 ± 0.2%, P = NS; P = 0.04 for exenatide versus saline group at the study end; Figure 3E). Further, 
when adjusted for changes in β cell volume, insulin secretion (insulin secretion AUC/β cell volume) 
was decreased by 32% of  the basal level in the exenatide-treated group, indicating an unloading of  
the β cell, while insulin secretion (AUC)/β cell volume increased by 81% of  the basal value in the 
saline-treated group (Table 2), indicating hyperstimulation.
Figure 2. Effect of exenatide on insulin secretion and sensitivity. (A) AUC insulin, (B) AUC C-peptide, (C) insulin sensitivity index (M/I), and (D) disposition 
index during the 2-step hyperglycemic clamp with arginine stimulation performed before (shown in black) and after (shown in red) treatment with exen-
atide or saline and in SHAM-operated baboons. Number of baboons: 12 in exenatide group, 12 in saline group, and 4 in SHAM group. Comparisons between 
baseline and after-treatment data were performed by Wilcoxon’s test. Comparison of clinical data between the study groups was performed by using a 
general linear model for multiple comparisons with adjustment for age and body weight. *P ≤ 0.05; **P ≤ 0.01
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To examine potential mechanisms responsible for the growth-promoting effect of  exenatide, we stained 
pancreatic sections with replication and apoptosis markers Ki67/MIB-1 and M30, respectively (Supple-
mental Figure 6, A and B, and Figure 4, A–C). We observed a marked increase in the percentage of  islet 
cells undergoing replication in the exenatide group, while there was no change in Ki67+ cells in the saline 
controls (Figure 4A). Using immunofluorescence, the replication marker Ki67 colocalized with insu-
lin-positive cells, confirming that β cells were among the islet cells undergoing replication with exenati-
de treatment (Supplemental Figure 7). Further, we observed that the replication marker Ki67 colocalized 
with glucagon-positive cells in exenatide-treated baboons (Supplemental Figure 8), indicating that treat-
ment with exenatide also stimulated α cells’ replication. As compared to baseline, the percentage of  M30+ 
cells was not significantly different at study end in the exenatide group but was significantly increased in 
the saline-treated control group (Figure 4B), indicating decreased apoptosis in the islets of  baboons who 
received exenatide compared with saline. After exenatide treatment, the percentage of  islet cells staining 
positive for the transdifferentiation marker c-KIT was significantly increased compared with baseline (P = 
0.01), and it was significantly higher than in saline-treated baboons (P = 0.01) (Figure 4C, Supplemental 
Figure 6C). Immunofluorescence demonstrated the presence of  cells staining positive for both c-KIT and 
insulin (Supplemental Figure 9), documenting that islet β cells were among the cells undergoing transdif-
ferentiation in the exenatide group. Colocalization of  insulin and somatostatin was not observed before or 
after treatment with either exenatide or saline (Supplemental Figure 10).
Figure 3. Effect of exenatide on pancreatic islet volumes. (A) The anatomic composition/relative volume of pancreatic islet from different regions of the 
pancreas obtained in animal/baboon controls. (B) Whole-islet volumes before (black) and after (red) the different treatments are shown. (C–E) The β cell, 
α cell, and δ cell volumes before (black) and after (red) treatment in the 3 groups. Islet volume and relative islet β, α, and δ cell volume were assessed by 
using computer assisted stereology toolbox (CAST) and expressed as percentage of total pancreas. Number of sections for each baboon: 10 (5 sections 
at baseline and 5 sections at the end of the study) evaluated twice. Comparisons between baseline and after-treatment data for each study group were 
performed by Wilcoxon’s test. A general linear model for multiple comparisons adjusted for age and body weight was used to test differences in relative 
islet/cell volumes between exenatide- versus saline-treated animals.
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Exenatide resulted in islet cell ultrastructural changes consistent with protection from cellular stress and secretory 
dysfunction. Electron microscopy was undertaken to visualize islet cell ultrastructure and β cell secretory 
granule morphology and composition before and after treatment in the exenatide and saline groups (Figure 
5 and Supplemental Figure 11). At baseline, both α and β cells were normal in appearance and well gran-
ulated in both groups. However, in partially pancreatectomized baboons receiving saline, the appearance 
of  degenerative features, including pycnotic nuclei and darkened cytoplasm, indicative of  apoptosis, was 
observed in both α and β cells. Poorly granulated β cells also were present in the saline-treated group (Figure 
5 and Supplemental Figure 11). In contrast, normal cellular ultrastructure with well-granulated β cells was 
preserved after PPx in the exenatide-treated group (Figure 5 and Supplemental Figure 11). Further assess-
ment of  insulin secretory granules revealed that, after treatment with exenatide, the pancreata of  baboons 
had fewer large, electron-clear progranules (P = 0.03) and more electron-dense mature granules (P = 0.01) 
relative to the saline control group (Figure 6, A–D). The amount of  total granules was unchanged by exen-
atide but was increased after saline (P = 0.01) because of  an increased number of  progranules (Figure 6E).
Immunogold labeling with electron microscopy provided further support for normal β cell secretory 
function following exenatide treatment (Figure 7). The number of  proinsulin-labeled granules was greater 
in the saline-treated group compared with the exenatide-treated baboons (Figure 7, A–D). Insulin appear-
ance inside the granules remained unchanged from baseline to the end of  the study in the exenatide group 
(Figure 7, C and D). Consistent with these findings, the plasma proinsulin concentration during the hyper-
glycemic clamp was significantly lower after exenatide treatment (Supplemental Figure 12).
In the saline-treated group β cells had morphological changes consistent with endoplasmic reticulum 
and mitochondrial stress (Figure 8). Specifically, in the saline-treated group mitochondrial cristae were 
disordered, and endoplasmic reticulum and Golgi membranes showed features of  degeneration (Figure 
8B); such changes in mitochondrial, endoplasmic reticulum, and Golgi structure were not found in the 
exenatide-treated group (Figure 8D). Collectively, the electron microscopic findings are consistent with a 
phenotype of  whole-islet and β cell stress and are consistent with the functional defect in insulin secretion 
induced by PPx. In contrast, the islets of  exenatide-treated animals were protected from these structural 
and functional abnormalities.
Discussion
GLP-1 RAs improve glucose control through several and, as of  yet, not completely understood mechanisms, 
including glucose-dependent enhancement of  insulin secretion and inhibition of  glucagon release (16–19, 33).
We report the first direct evidence, we believe, in a nonrodent species for enhanced β cell replication and 
decreased β cell apoptosis and cellular stress following chronic exenatide administration. Because the genetic 
background of  baboons closely resembles that of  humans, this observation raises the possibility that GLP-1 
RA can stimulate β cell proliferation in humans if  a sufficiently high plasma GLP-1 RA concentration can be 
achieved. We also observed an increase in whole-body insulin sensitivity after exenatide treatment in associ-
ation with a compensatory decrease in insulin secretion. Notably, the disposition index increased following 
exenatide treatment, indicating that intrinsic β cell secretory function was enhanced by exenatide treatment in 
face of  increased insulin sensitivity. Further, the percentage increase in the disposition index was greater than 
the percentage increase in β cell volume (an indirect measure of  β cell mass), indicating that exenatide exerts 
independent actions both to stimulate β cell proliferation and to augment β cell function.
The partially pancreatectomized baboon model was designed, based on the partially pancreatectomized 
rat (34), to generate a robust translational model of  early-stage β cell loss with emerging features of  cellular 
stress, secretory dysregulation, and islet cell apoptosis. We believe that this goal was achieved because 13 
Table 2. Discordant effects of exenatide or saline treatments on the β cell function adjusted for the corresponding β cell volume
Exenatide 
(baseline)
Exenatide  
(study end)
Δ vs. baseline Saline (baseline) Saline (study end) Δ vs. baseline
Insulin secretion (AUC) 29,243 16,910 –43% 16,399 16,862 +2%
β cell volume (%) 5.6 4.7 –17% 5.5 3.12 –44%
Insulin secretion (AUC)/β 
cell volume (%)
5230 3597 –32% 2981 5404 +81%
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weeks after PPx, baboon islets and β cells showed morphological features of  cellular stress and secretory 
granule dysregulation with increased proinsulin concentrations, all consistent with emerging insulin secre-
tory dysfunction. Of  note, the mean relative β cell volume was reduced by 43% in the saline-treated group, 
which is consistent with the β cell deficit Butler et al. reported in humans with impaired fasting glucose (4).
Morphometric analysis of  pancreatic sections obtained before and after treatment supported the bene-
ficial and protective effect of  exenatide on whole-islet volume. Relative volumes of  all islet cell types, and 
in particular β cells, were preserved after exenatide treatment, while islet cell volumes were reduced in the 
saline-treated control group. When the difference in islet cell volumes in the different regions of  the baboon 
pancreas are taken into account (i.e., lower in the tail compared with the head-body), it is clear that treatment 
with exenatide increased islet β, α, and δ cell volumes. This is supported by the finding that the volumes of  
all 3 islet cell types were similar, or even higher, in the head-body of  exenatide-treated baboons than in the 
tail of  anatomic controls. The increased islet cell volumes after exenatide treatment are due to increased cell 
replication and reduced cell apoptosis as demonstrated by Ki67 and M30 immunostainings, respectively. Islet 
volume depends on the balance between islet cell proliferation and apoptosis. As demonstrated in the present 
study, exenatide promotes islet cell proliferation, while simultaneously reducing apoptosis as compared with 
saline treatment. In particular, we found that exenatide treatment induced a 5-fold increase in islet cells’ rep-
lication as indicated by Ki67 immunostaining. In comparison with baseline, the number of  islet cells under-
going apoptosis was 1.6-fold increased in exenatide-treated baboons, although not significantly; in contrast, 
it was increased by 3.4-fold in saline-treated animals. From the quantitative standpoint a 5-fold increase in 
replication coupled with a 1.6-fold increase in apoptosis, with a starting islet cell volume of  3.2% of total pan-
creas, would be expected to produce an expansion of  approximately 2-fold of  islet cell volume over 13 weeks. 
Drugs affecting islet cells’ proliferation and apoptosis are well known, but they have been studied mainly in 
rodent models (35–38) and never in nonhuman primates or humans. Recently, liraglutide, a human GLP-1 
analog, was shown to increase islet mass by stimulating β cell proliferation and reducing β cell apoptosis by 
enhancing nephrin expression, a protein involved in β cell survival signaling, and by stimulating PI3K-depen-
dent Akt phosphorylation (39). Conversely, in the study by Bunck et al. (19), 52 weeks of  exenatide treatment 
did not exert any proliferative effect on β cell mass because within weeks of  discontinuing exenatide therapy 
in patients with T2D, insulin secretion declined to pretreatment level. However, after 3 years of  treatment, 
exenatide resulted in increased insulin sensitivity along with improved β cell function that were sustained 
after cessation of  treatment for 4 weeks (40). Our results, although generated in partially pancreatectomized 
baboons treated with continuous IV exenatide administration, which could have induced a certain degree of  
GLP-1 receptor desensitization, are consistent with those of  Bunck et al. (40). Notably, at study end serum 
exenatide levels were higher (758 ± 162 pg/mL) in the exenatide group compared with the saline group (0.0 
pg/mL) and 4-fold higher than those achieved in diabetic patients treated with exenatide (41). Thus, our 
results raise the intriguing possibility that if  the plasma exenatide concentration can be raised sufficiently high, 
it might be possible to stimulate β cell proliferation and increase β cell mass.
Figure 4. Effect of exenatide on islet cell replication and apoptosis. (A) The percentage of the islet cells positive for the replication marker Ki-67 nuclear 
protein (antibody MIB-1) before (black) and after the treatments (red). (B) The percentage of the islet cells positive for the apoptosis marker M30 before 
(black) and after (red) treatment. (C) The percentage of islet cells positive for the hematopoietic stem cell marker c-KIT before (black) and after (red) 
treatment with exenatide or saline. Number of sections for each baboon: 4 (2 sections at baseline and 2 sections at the end of the study). Comparisons 
between baseline and after-treatment data for each study group were performed by Wilcoxon’s test. A general linear model for multiple comparisons 
adjusted for age and body weight was used to test differences between exenatide- and saline-treated animals.
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After exenatide treatment we also detected a significant number of  cells that stained positive for the 
stem cell marker c-KIT (P = 0.01), which has been shown to be involved in islet development and β cell pro-
liferation, maturation, and survival (42, 43). c-KIT+ cells were demonstrated both in islets and in ducts, and 
a fraction of  them costained for insulin. Conversely, c-KIT+ cells were absent in all groups before treatment 
and were absent after treatment in the saline-treated group. These findings are in agreement with those 
described in a previously published study, in which we observed c-KIT+ cells coexpressing insulin in pan-
creatic ducts of  baboons treated with exenatide (31). However, the absence of  cells costaining for insulin 
and somatostatin, as observed in states of  stimulated β cell neogenesis, suggests that increased replication, 
rather than neogenesis, accounts for exenatide-stimulated β cell growth in the present study.
Safety concerns have emerged about the potential proliferative effects of  exenatide and other GLP1 
RAs, although causal evidence for a link between exenatide and pancreatic cancer is lacking. We recently 
reported that chronic infusion of  exenatide for 14 weeks did not induce pancreatitis, parenchymal or peri-
ductal inflammatory cell accumulation, ductal hyperplasia, or dysplastic lesions/pancreatic intraepithelial 
neoplasia in baboons (31). Similarly, in the present study no inflammatory or neoplastic changes were 
observed, and there was no increase in plasma amylase concentration in exenatide-treated baboons. Impor-
tantly, although serum exenatide levels were markedly increased at the end of  the study, no side effects, 
including vomiting and anorexia, were observed in exenatide-treated animals.
Figure 5. Representative figure of electron microscopy of pancreatic specimens taken before and after treatment with exenatide or saline. At baseline 
both β and α cells appeared healthy and well granulated. After exenatide treatment β and α cells continued to appear healthy and well granulated. Con-
versely, after treatment with saline, both cell types showed degenerative features, including pycnotic nuclei (arrows) and dark cytoplasm, indicative of 
ongoing apoptosis and poorly granulated β cells. Scale bar: 2000 nm.
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During the repeat hyperglycemic clamp at study end, exenatide-treated baboons had lower insulin 
secretory responses to both glucose and l-arginine compared with the basal, pretreatment hyperglycemic 
clamp study. The decrease in insulin secretion most likely was attributable to the concomitant increase in 
insulin sensitivity. However, when insulin secretion was related to the degree of  insulin resistance (dispo-
sition index), exenatide treatment resulted in a significant, almost 2-fold increase in β cell function. This 
observation is consistent with prior studies with exenatide in humans (44). Recent studies by us (45, 46) 
support an insulin-sensitizing effect of  exenatide in both muscle and liver. Accordingly, we have reported 
that GLP-1 receptor protein is expressed in the skeletal muscle and liver of  baboons, and it also is present in 
human skeletal muscle (45). Other studies also suggest that exenatide improves insulin sensitivity, indepen-
dent of  changes in body weight (47–49). In the present study, treatment with exenatide did not change total 
body weight or lean body mass. Although total body fat mass declined in exenatide-treated baboons, a sim-
ilar decrease was observed in saline-treated animals in whom insulin sensitivity did not increase. Because 
the suppression of  plasma glucagon during the hyperglycemic clamp was similar in all groups, differences 
in plasma glucagon concentration cannot explain the increase in insulin sensitivity in the exenatide-treated 
group. Therefore, the increase in insulin sensitivity observed after exenatide treatment most likely was due 
to a direct insulin-sensitizing effect. Levels of  phosphorylated Akt (p-Akt) Ser473 increased significantly (P = 
0.03) in skeletal muscle of  exenatide-treated baboons compared with baseline and with saline-treated con-
trols and could, at least in part, play a role in the increase in insulin sensitivity. No significant changes were 
observed in any other mediators of  insulin action in muscle. In the liver, among the measured mediators 
of  insulin action, the only change that we found was a decrease in ERK phosphorylation, which is not a 
typical mediator of  insulin’s effect on glucose metabolism. Therefore, it is unlikely that the insulin-sensitiz-
Figure 6. Effect of exenatide on the maturation process of insulin granules. (A) Baboon pancreatic β cell contains classic, electron-dense, mature insulin 
granules (indicated by red arrows) as well as immature larger and electron-clear (indicated by blue arrows) insulin containing progranules. (B) After PPx and in 
vivo exenatide treatment, a decrease in immature granules and an increase in the number of mature granules were observed. Mean values from (C) quanti-
tation of insulin progranules and (D) mature insulin granules and (E) total number of granules (progranules + mature granules) before (black) and after (red) 
exenatide and saline treatment in the pancreas of nonhuman primates. Number of baboons: 4 at baseline and 4 after treatment for both groups. Comparisons 
between baseline and after-treatment data for each study group were performed by Wilcoxon’s test. A general linear model for multiple comparisons adjusted 
for age and body weight was used to test differences between exenatide- versus saline-treated animals. *P ≤ 0.01. Scale bar: 2000 nm.
1 1insight.jci.org   https://doi.org/10.1172/jci.insight.93091
R E S E A R C H  A R T I C L E
ing effect of  exenatide can be attributed to an increase in insulin signal transduction, which suggests that 
exenatide may exert its insulin-sensitizing effect on postreceptor postsignaling intracellular pathways. Con-
sistent with this, we recently demonstrated that exenatide activates glucose transport by an AMP-activated 
protein kinase–dependent mechanism in vitro (45).
Electron microscopy (EM) showed that the β cells of  exenatide-treated baboons were healthy and 
replenished with mature insulin granules, as evidenced by the typical presence of  high–electron density, 
precipitated, crystalline insulin. In contrast, the β cells of  saline-treated controls showed signs of  distress, 
including condensed pycnotic nuclei and pale, immature granules, indicative of  accelerated insulin secre-
tion, β cell stress, and emerging β cell exhaustion. These ultrastructural findings are consistent with the 
increased number of  apoptotic cells found in the islets of  saline-treated baboons. This improved histologi-
cal picture of  β cell health can be explained by one or both of  the following mechanisms: (a) a direct effect 
of  exenatide on the β cell to reduce stress and apoptosis and (b) an unloading of  the β cell with reduction 
in insulin secretion secondary to the improvement in insulin sensitivity. Thus, exenatide treatment reduced 
insulin secretion by 32%, whereas treatment with saline resulted in an 81% increase compared with the 
basal pretreatment value. This is of  importance because β cell rest diminishes β cell immunogenicity (49) 
and renders β cells less vulnerable to cytotoxic insults (50–52).
Research trials and clinical practice have shown that treatment with exenatide causes body weight and 
fat mass reduction (16–19) secondary to decreased energy intake (53). However, it has been hypothesized 
that GLP-1 RAs also might be involved in the regulation of  energy metabolism (54–56). Although we 
found a significant decrease in fat mass in exenatide-treated baboons, a similar decrease in fat mas was 
observed in the saline-treated groups at study end. Lean mass and body weight were slightly decreased after 
saline treatment; similarly, a small but insignificant decrease in lean mass and body weight was found in the 
exenatide group. Overall, these variations in body composition are modest in both study groups and may 
be the consequence of  surgery and long-term catheterization rather than an effect of  exenatide or saline 
treatment. Food intake did not differ between exenatide-treated and saline-treated baboons, indicating that 
the dose of  exenatide used in the present study did not alter energy intake.
Figure 7. Effect of exenatide on proinsulin and insulin secretory granules. Electron microscopy of pancreatic specimens 
before (A and C) and after in vivo treatment with saline (B) or exenatide (D). Images show immunogold labeling for the 
presence of insulin-containing (12 nm) and proinsulin-containing (18 nm) secretory granules. Proinsulin-labeled granules 
(arrows) were more numerous in the saline-treated (B) than in the exenatide-treated animals (D).Scale bar: 500 nm.
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A number of limitations should be considered when interpreting our results. First, we studied only female 
baboons. Although this methodological approach, which commonly is used in animal-based studies, makes the 
results more homogeneous, whether our results can be generalized to male primates needs to be established. 
Second, we did not measure energy expenditure; therefore, we cannot firmly establish that exenatide does not 
affect energy expenditure. However, the observation that body weight and food consumption were stable during 
the study period in the 2 experimental groups does not support a significant change in energy expenditure. We 
did not observe significant differences in fasting plasma glucose and HbA1c levels between exenatide, saline, 
or SHAM groups, indicating that baboons in the 3 study groups did not develop diabetes. This most likely is 
explained by the surgical PPx, which removed only a relatively small portion of the pancreas (about one-third of  
the pancreas), which was followed by a compensatory increase in insulin secretion by the remaining pancreas. 
However, we have no data regarding postprandial glucose levels. Although we cannot exclude the possibility 
that there were differences in postprandial glucose levels between saline- and exenatide-treated animals, we think 
that this is unlikely because the HbA1c, as well as the fasting glucose, was similar in the 2 experimental groups.
In conclusion, chronic intravenous exenatide administration causes (a) an approximately 2-fold 
increase in β cell function; (b) a significant increase in β cell volume, which results primarily from an 
increase in β cell proliferation; (c) a major improvement in β cell health and reduced β cell stress as demon-
strated by routine and EM histology; and (d) an improvement in total body insulin sensitivity. This study 
provides solid grounds for further studies aimed at exploring GLP1 RAs’ capability to preserve β cell mass 
in patients with diabetes and in subjects at high risk of  developing diabetes and for investigating in more 
detail the pharmacodynamics of  antidiabetic drugs, including GLP1 RAs, in baboons.
Figure 8. Exenatide resulted in islet cell ultrastructural changes consistent with protection from cellular stress. Electron microscopy of pancreatic 
specimens taken before (A and C) and after treatment with saline (B) or exenatide (D) showing organelle features in islet cells. At the end of the study in 
the saline-treated group, mitochondrial cristae were disordered, and endoplasmic reticulum and Golgi membranes showed features of degeneration; such 
changes in mitochondrial, endoplasmic reticulum, and Golgi structure were absent in the exenatide-treated group. MIT: mitochondria; GR: granules; RER/
RIB: rough endoplasmic reticulum/ribosomes. Scale bar: 500 nm.
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Methods
Study population. Twenty-eight female, nondiabetic baboons (Papio hamadryas sp.) aged 13 ± 3 years were 
randomly selected from the colony of  the Southwest National Primate Research Center at Texas Biomed-
ical Research Institute (San Antonio, Texas, USA) using previously published criteria (26). Twenty-four 
animals underwent abdominal surgery to resect the tail of  the pancreas (PPx) and then were randomized 
to receive an intravenous infusion of  saline (n = 12; age = 12 ± 2 years) or exenatide (n = 12; age = 13 ± 3 
years) for 13 weeks. Four animals underwent sham abdominal surgery without PPx followed by a chronic 
saline intravenous infusion (SHAM; n = 4; age = 13 ± 2 years) for 13 weeks.
Each animal was housed in a single cage with ad libitum access to water and food. The amount of  food 
consumed by each animal was registered daily. Experimental protocols were approved by the Institutional 
Animal Care and Use Committee (IACUC) of  the Texas Biomedical Research Institute and the University 
of  Texas Health Science Center at San Antonio.
Before treatment baboons underwent a body composition analysis and long-term catheterization for 
blood collection and drug infusion by placing heparin-coated polyurethane catheters (SoloCath catheters, 
Harvard Apparatus, Holliston, Massachusetts, USA) in the internal jugular vein and carotid artery. Catheters 
were routed subcutaneously to the midscapular region, where they were connected to the tether jacket chronic 
infusion system (31, 57). Three days after catheterization (i.e., before abdominal surgery), a 2-step hypergly-
cemic clamp with arginine (10% arginine hydrochloride, Hospira, Pfizer, Lake Forest, Illinois, USA) stimu-
lation was performed. Within 3 to 5 days after the hyperglycemic clamp, abdominal surgery was performed 
as described below and total parenteral nutrition was started. After a 96-hour recovery period, baboons were 
fed again with standard chow and were chronically infused (24 h/d) for 13 weeks with either normal saline 
or exenatide (Byetta, Amylin Pharmaceuticals, San Diego, California, USA) diluted in normal saline at the 
rate of  0.014 μg/kg/h, as previously described (31). At the end of  the 13-week treatment period, following a 
72-hour washout period, baboons underwent a second body composition analysis and a 2-step hyperglycemic 
clamp with arginine stimulation. Baboons were then euthanized and the whole pancreas from the SHAM 
group and the remnant pancreas (head-body) from the other 2 groups was harvested.
An additional group of  16 baboons (8 males, 8 females) was studied as controls for pancreatic anatomy. 
Their whole pancreata were removed at necropsy to determine the difference in islet histology and islet cell 
volumes in the tail versus head-body of  the pancreas.
Body composition analysis. Baboons underwent a dual-energy x-ray absorptiometry scan (Lunar Prodigy 
Whole Body Scanner; GE Medical Systems, Madison, Wisconsin, USA) to determine fat-free mass, fat 
mass, percentage body fat, and bone mineral content. Scanning was performed on ketamine-sedated ani-
mals, and data were analyzed using the software Encore2007 (GE Healthcare, Madison, Wisconsin, USA).
Hyperglycemic clamp. After a 10- to 12-hour overnight fast, baboons were sedated and intubated endotra-
cheally under direct laryngoscopic visualization. Deep anesthesia was induced using a mix of  oxygen and 
inhaled isofluorane (1.5% v/v). After 60–90 minutes to allow animal stabilization, a 2-step hyperglycemic 
clamp with arginine stimulation was performed (58). From 0–90 minutes the plasma glucose concentration 
was raised by 100 mg/dL (i.e., from ~90 to 190 mg/dL), and from 90–180 minutes the plasma glucose 
concentration was raised by an additional 100 mg/dL (i.e., from ~190 to 290 mg/dL). At 180 minutes 
animals received a bolus (0.5 g/kg of  body weight) injection of  arginine, and the animals were followed for 
an additional 30 minutes. Plasma glucose concentration was measured every 2 minutes from 0–10, 90–100, 
and 180–190 minutes and every 5–10 minutes from 10–90, 100–180, and 190–220 minutes. Glucose was 
measured by using a glucose analyzer (GM9 Glucose Analyzer, Analox Instruments, Lunenburg, Massa-
chusetts, USA) and insulin, glucagon, and C-peptide by radioimmunoassay (27). The following parameters 
were computed: (a) AUC for insulin and C-peptide concentration (0–210 minutes) was calculated by using 
the trapezoidal rule; (b) ISR was calculated from deconvolution of  the plasma C-peptide concentration 
(59); (c) hepatic insulin clearance was computed as ISR/plasma insulin concentration during the hyper-
glycemic clamp (60); (d) insulin sensitivity was assessed by the M/I index (61), where the M value is the 
whole-body glucose disposal rate calculated from the glucose infusion rate during the last 30 minutes of  
the hyperglycemic clamp (150–180 minutes), corrected by the changes in glucose pool, divided by the mean 
plasma insulin concentration during the same period; and (e) β cell function was estimated by the so-called 
disposition index, calculated by multiplying the ISR by insulin sensitivity measured by M/I (3). 
PPx. PPx was performed under general anesthesia with isofluorane 1.5% v/v as previously described 
(31) by making an incision on the mesoduodenum or omentum on each side of  the pancreas to mark the 
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portion to be removed. The pancreas then was ligated immediately proximal to the marks, and the distal 
part (tail), accounting for about 30% of  the pancreas, was removed and collected for histological analysis 
before the start of  treatment. Previous studies in primates and humans have shown that more than 50% of  
the pancreas mass must be excised to stimulate compensatory β cell regeneration (62, 63). SHAM-operated 
baboons underwent a sham surgical procedure similar to that in the other 2 study groups without undergo-
ing PPx. Following the surgery, intravenous parenteral nutrition with 5% glucose solution, potassium, and 
amino acids was provided during a recovery period of  4 days along with antibiotics and analgesics. The 
perioperative/postoperative mortality was 0%. Solid food was again introduced after the recovery period, 
and baboons were housed inside individual cages while on tether for treatment (31).
Western blots for insulin signaling. Skeletal muscle and liver samples were obtained following the sec-
ond 2-step hyperglycemic clamp (i.e., after 13 weeks of  exenatide or saline infusion) and frozen in liquid 
nitrogen. Western blot experiments were performed as described previously (64) using antibodies against 
IR-β (Santa Cruz Biotechnology, Dallas, Texas, USA), IRS-1 (Thermo Fisher Scientific, Pittsburgh, Penn-
sylvania, USA), Akt and p-Akt (Ser473), ERK and p-ERK (Thr202/Tyr204), JNK and p-JNK (Thr183/
Tyr185), PTEN (Cell Signaling Technology, Beverly, Massachusetts, USA), and PHLPP1 (made in-house). 
Histology, immunohistochemistry, and EM. Pancreatic specimens (tail and head-body portion) were 
fixed in 10% formalin solution and embedded in paraffin for histological and immunohistochemical 
analyses. Paraffin sections, 4 μm thick, were stained for hematoxylin and eosin or processed by a 
Ventana Immunostainer (BenchMark-XT, Ventana Medical Systems, Inc., Tucson, Arizona, USA) for 
immunostaining for insulin (Insulin Cell Marque immuno-antibody, Ventana Medical Systems, Inc.), 
glucagon (Novocastra Glucagon antibody by Leica Microsystems, Inc., Bannoockburn, Illinois, USA), 
somatostatin (Somatostatin Cell Marque rabbit polyclonal antibody, Ventana Medical Systems, Inc.), 
and c-KIT (c-Kit rabbit polyclonal antibody, Cell Signaling Technology). Stained sections were then 
analyzed by CAST (Olympus 2.0 system, Olympus America Inc., Melville, New York, USA) to quanti-
tate islet volume and relative islet β, α, and δ cell volumes, using the stereology fundaments previously 
described on pancreatic sections randomly collected from the pancreas tail (basal) and head and body 
at the end of  the study. The operator was blinded to the status of  the baboon, and the reproducibility 
of  the measurements was estimated twice in 5 specimens with a coefficient of  variation less than 5%. 
Each field of  the slide was randomly selected using the CAST meander sampling. On average, we ana-
lyzed 125 ± 46 islets per animal per group on each slide, before and after treatment. Pancreas weight 
at baseline was 6.8 ± 1.8 g vs. 6.4 ± 1.8 g for the exenatide and saline groups, respectively (P = 0.788); 
at the end of  the study, pancreas weight was 12.8 ± 2.4 vs. 14.5 ± 3.9 g (P = 0.271), respectively. Data 
obtained from CAST were expressed as percentage of  total pancreas as previously described (30). Islet 
cell proliferation was measured by counting the number of  Ki67-immunoreactive cells detected using 
the MIB-1 antibody (Dako, Carpinteria, California, USA). The number of  apoptotic islet cells was 
evaluated using the monoclonal antibody M30 (Roche, Penzberg, Germany), which recognizes the 
caspase-cleaved, formalin-resistant epitope of  cytokeratin 18.
For ultrastructural morphological analyses, pancreatic specimens of  4 saline-treated (before the start 
of  saline treatment) and 4 exenatide-treated (before the start of  exenatide treatment) baboons were fixed 
for 2 hours at 4°C in 2% paraformaldehyde and 2% glutaraldehyde in 0.05 M pH 7.3 cacodylate buffer 
(Karnovsky fixative, EMS, Domat/Ems, Switzerland), postfixed in 1% osmium tetroxide, and embedded 
in Epon-Araldyte (Honeywell-FLUKA, Seelze, Germany). For ultrastructural immunocytochemistry, thin 
sections were pretreated with sodium metaperiodate for 30 minutes, then placed onto a drop of  ovalbumin 
for 5 minutes, transferred onto a drop of  antiproinsulin (monoclonal mouse antiproinsulin, DSHB, Gen-
tofte, Denmark), diluted 1:10 overnight, then after rinses transferred onto a drop of  anti-insulin (polyclonal 
guinea pig anti-insulin, Dako, Glostrup, Denmark), diluted 1:50 overnight, and subsequently, after rinses, 
transferred onto a mixture of  18 nm colloidal gold-AffiniPure (Jackson ImmunoResearch, West Grove, 
Pennsylvania, USA) goat antimouse diluted 1:20 and of  12 nm colloidal gold-AffiniPure donkey anti–
guinea pig diluted 1:20. In control experiments the primary antibodies were omitted. All thin sections were 
counterstained with uranyl acetate and lead citrate and observed with a Morgagni Philips/Thermo Fisher 
Scientific electron microscope (FEI Company, Endovehn, the Netherlands).
For the evaluation of  secretory, mature granules and progranules of  β cells, 4 cells for each group 
(before and after saline treatment and before and after exenatide treatment) were evaluated. The immuno-
gold labelings were evaluated with a semiquantitative method.
1 5insight.jci.org   https://doi.org/10.1172/jci.insight.93091
R E S E A R C H  A R T I C L E
Immunofluorescence staining. Pancreatic sections, 3-μm thick, were fixed and immunostained as previ-
ously described (31, 65). The following antibodies were used: anti-insulin guinea pig monoclonal (Dako), 
anti–c-KIT mouse monoclonal antibody (Cell Signaling Technology), anti-KI67 rabbit polyclonal antibody 
(Cell Signaling Technology), and antisomatostatin mouse monoclonal antibody (Dako). Islets were imaged 
using a BioRad MRC 1024 confocal laser scanning microscope (BioRad, Hercules, California, USA). Con-
focal images were acquired sequentially, using the LaserSharp2000 software with a low iris diameter (66).
Controls for regional differences in islet cell volume. It is well established that there are significant differences 
between the number of  islets in the tail versus head-body of  the pancreas. To ensure accurate comparison 
of  islet cell volumes before and after PPx (tail vs. head-body), we measured α, β, and δ cell volumes in both 
the tail and head-body regions from whole, intact pancreases obtained from a representative sample of  16 
randomly selected baboons that did not participate in the study.
Statistics. Data for continuous variables are given as the mean ± SD. Given the small sample size (12 
baboons in saline group, 12 in exenatide group, and 4 animals in SHAM group, n = 28), nonparametric 
tests were carried out to analyze the data.
Differences in clinical data among the study groups were evaluated by using a general linear model 
with post hoc Fisher’s least significant difference correction for pairwise comparisons.
To compare changes between baseline and end-of-study parameters in each study group, we used Wil-
coxon’s test. Statistical analyses were performed by using Stata/SE Version 11.2 (Stata Corp LP, College 
Station, Texas, USA). We considered a 2-sided P value no more than 0.05 statistically significant.
Study approval. Experimental protocols were approved by the IACUC of  the Texas Biomedical Research 
Institute and the University of  Texas Health Science Center at San Antonio.
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